Ann: Quarterly Activity Report and Appendix 4C, page-25

Daniel, all I can do is try to imagine how fund managers and potential high net worth investors view RAC. I am guessing that, for most, the optics would look bad: a a biotech that listed in July 2016 (8 years ago) but in all that time has not (personally) treated one patient.

I know the real story isn’t as dire-sounding as that, but I imagine most funds and potential high net worth investors would see the RAC story like that.

But as I said, this is just my best guess.

You and Pete presented at the Bioshares conference where all the biotech execs and fund managers and high net investors interested in biotech gather….what did those people say to you at the conference?

What were their concerns or criticisms or misconceptions, if any, that they shared with you?

Also, what did they like?

Do you think they managed to get it—that bisantrene truly is something special?

I don’t mean the polite talk…where people feel obliged to stroke each other and say nice things. I mean the genuine unsolicited comments, both good and bad?

I guess, apart from holding my breath waiting for the first patient to get treated, I am also holding my breath waiting to see a new quality fund on the register!